220 related articles for article (PubMed ID: 20435152)
1. Uni- or bi-ventricular hypertrophy and susceptibility to drug-induced torsades de pointes.
Panyasing Y; Kijtawornrat A; Del Rio C; Carnes C; Hamlin RL
J Pharmacol Toxicol Methods; 2010; 62(2):148-56. PubMed ID: 20435152
[TBL] [Abstract][Full Text] [Related]
2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
3. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
4. Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes.
Lengyel C; Varró A; Tábori K; Papp JG; Baczkó I
Br J Pharmacol; 2007 Aug; 151(7):941-51. PubMed ID: 17533421
[TBL] [Abstract][Full Text] [Related]
5. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Lu HR; Hermans AN; Gallacher DJ
Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
[TBL] [Abstract][Full Text] [Related]
6. Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation.
Lu HR; Remeysen P; De Clerck F
J Cardiovasc Pharmacol; 2000 Dec; 36(6):728-36. PubMed ID: 11117372
[TBL] [Abstract][Full Text] [Related]
7. Measuring the risk of torsades de pointes: electrocardiographic evaluation of PNU-142093 in conscious cynomolgus non-human primates using restraint and non-restraint procedures.
Bass AS; Hanson LA; Jackson TA
J Pharmacol Toxicol Methods; 2009; 60(1):51-7. PubMed ID: 19447184
[TBL] [Abstract][Full Text] [Related]
8. Negative electro-mechanical windows are required for drug-induced Torsades de Pointes in the anesthetized guinea pig.
Guns PJ; Johnson DM; Weltens E; Lissens J
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):125-34. PubMed ID: 22516473
[TBL] [Abstract][Full Text] [Related]
9. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
Lu HR; Gallacher DJ; Yan GX
J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
[TBL] [Abstract][Full Text] [Related]
10. Potentially modifiable factors of dofetilide-associated risk of torsades de pointes among hospitalized patients with atrial fibrillation.
Naksuk N; Sugrue AM; Padmanabhan D; Kella D; DeSimone CV; Kapa S; Asirvatham SJ; Lee HC; Ackerman MJ; Noseworthy PA
J Interv Card Electrophysiol; 2019 Mar; 54(2):189-196. PubMed ID: 30353374
[TBL] [Abstract][Full Text] [Related]
11. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive cardiac activation imaging of ventricular arrhythmias during drug-induced QT prolongation in the rabbit heart.
Han C; Pogwizd SM; Killingsworth CR; Zhou Z; He B
Heart Rhythm; 2013 Oct; 10(10):1509-15. PubMed ID: 23773986
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation.
Liu G; Xue X; Gao C; Huang J; Qi D; Zhang Y; Dong JZ; Ma CS; Yan GX
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28522677
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced QT prolongation and sudden death.
Del Rosario ME; Weachter R; Flaker GC
Mo Med; 2010; 107(1):53-8. PubMed ID: 20222297
[TBL] [Abstract][Full Text] [Related]
15. Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome.
Diness TG; Yeh YH; Qi XY; Chartier D; Tsuji Y; Hansen RS; Olesen SP; Grunnet M; Nattel S
Cardiovasc Res; 2008 Jul; 79(1):61-9. PubMed ID: 18367457
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
17. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.
Wang WQ; Robertson C; Dhalla AK; Belardinelli L
J Pharmacol Exp Ther; 2008 Jun; 325(3):875-81. PubMed ID: 18322148
[TBL] [Abstract][Full Text] [Related]
18. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic and electrophysiologic effects of ontazolast in dogs.
Hamlin RL; Nakayama T; Brady JT; Stoll RE
Am J Vet Res; 2000 Nov; 61(11):1364-8. PubMed ID: 11108180
[TBL] [Abstract][Full Text] [Related]
20. Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block.
Oros A; Volders PG; Beekman JD; van der Nagel T; Vos MA
Heart Rhythm; 2006 Nov; 3(11):1339-45. PubMed ID: 17074641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
